Resource Summary

Clinical Question:
Is there a difference in efficacy between the new^ recombinant (Shingrix®) and the live (Zostavax®) zoster vaccines?

Bottom Line:
Recombinant zoster vaccine appears more efficacious than the live vaccine. Over three years^ recombinant zoster vaccine prevents one additional case of herpes zoster (shingles) for about every 40 patients treated compared to one for every 60-70 with live vaccine. Both vaccines decrease the risk of post-herpetic neuralgia. The recombinant vaccine is more expensive and requires two injections whereas the live vaccine only requires one.

Publication Date: 2018-11-19
Last Updated on PCR: 2018-11-20 14:38:24